vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and IDEX Corporation (IEX). Click either name above to swap in a different company.
IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $205.4M, roughly 1.9× COLLEGIUM PHARMACEUTICAL, INC). IDEX Corporation runs the higher net margin — 30.1% vs 8.3%, a 21.9% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 12.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $86.0M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs -29.4%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
COLL vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $398.4M |
| Net Profit | $17.0M | $120.0M |
| Gross Margin | 62.5% | 99.9% |
| Operating Margin | 29.6% | 43.3% |
| Net Margin | 8.3% | 30.1% |
| Revenue YoY | 12.9% | 16.7% |
| Net Profit YoY | 35.3% | 25.7% |
| EPS (diluted) | $0.48 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $205.4M | $899.1M | ||
| Q3 25 | $209.4M | $878.7M | ||
| Q2 25 | $188.0M | $865.4M | ||
| Q1 25 | $177.8M | $814.3M | ||
| Q4 24 | $181.9M | $862.9M | ||
| Q3 24 | $159.3M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $17.0M | $128.3M | ||
| Q3 25 | $31.5M | $127.8M | ||
| Q2 25 | $12.0M | $131.6M | ||
| Q1 25 | $2.4M | $95.5M | ||
| Q4 24 | $12.5M | $123.2M | ||
| Q3 24 | $9.3M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | 62.5% | 43.1% | ||
| Q3 25 | 61.7% | 44.5% | ||
| Q2 25 | 57.7% | 45.3% | ||
| Q1 25 | 54.8% | 45.3% | ||
| Q4 24 | 54.0% | 42.5% | ||
| Q3 24 | 60.8% | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | 29.6% | 20.4% | ||
| Q3 25 | 29.7% | 21.1% | ||
| Q2 25 | 18.7% | 21.7% | ||
| Q1 25 | 12.2% | 17.4% | ||
| Q4 24 | 20.9% | 19.2% | ||
| Q3 24 | 21.9% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | 8.3% | 14.3% | ||
| Q3 25 | 15.0% | 14.5% | ||
| Q2 25 | 6.4% | 15.2% | ||
| Q1 25 | 1.4% | 11.7% | ||
| Q4 24 | 6.9% | 14.3% | ||
| Q3 24 | 5.9% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $0.48 | $1.71 | ||
| Q3 25 | $0.84 | $1.70 | ||
| Q2 25 | $0.34 | $1.74 | ||
| Q1 25 | $0.07 | $1.26 | ||
| Q4 24 | $0.36 | $1.61 | ||
| Q3 24 | $0.27 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $586.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $4.0B |
| Total Assets | $1.7B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $386.7M | $580.0M | ||
| Q3 25 | $285.9M | $593.8M | ||
| Q2 25 | $222.2M | $568.2M | ||
| Q1 25 | $197.8M | $594.1M | ||
| Q4 24 | $162.8M | $620.8M | ||
| Q3 24 | $120.0M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $301.7M | $4.0B | ||
| Q3 25 | $274.8M | $4.0B | ||
| Q2 25 | $232.2M | $4.0B | ||
| Q1 25 | $234.4M | $3.9B | ||
| Q4 24 | $228.8M | $3.8B | ||
| Q3 24 | $234.3M | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $1.7B | $6.9B | ||
| Q3 25 | $1.6B | $7.0B | ||
| Q2 25 | $1.6B | $6.9B | ||
| Q1 25 | $1.6B | $6.8B | ||
| Q4 24 | $1.7B | $6.7B | ||
| Q3 24 | $1.6B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | $86.0M |
| FCF MarginFCF / Revenue | 59.6% | 21.6% |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $123.0M | $209.5M | ||
| Q3 25 | $78.4M | $203.5M | ||
| Q2 25 | $72.4M | $161.7M | ||
| Q1 25 | $55.4M | $105.7M | ||
| Q4 24 | $84.6M | $172.6M | ||
| Q3 24 | $-9.0M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $122.4M | $189.8M | ||
| Q3 25 | $78.3M | $188.7M | ||
| Q2 25 | $72.4M | $146.9M | ||
| Q1 25 | $54.6M | $91.4M | ||
| Q4 24 | $84.1M | $157.1M | ||
| Q3 24 | $-9.2M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | 59.6% | 21.1% | ||
| Q3 25 | 37.4% | 21.5% | ||
| Q2 25 | 38.5% | 17.0% | ||
| Q1 25 | 30.7% | 11.2% | ||
| Q4 24 | 46.2% | 18.2% | ||
| Q3 24 | -5.8% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 0.3% | 2.2% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.4% | 1.8% | ||
| Q4 24 | 0.3% | 1.8% | ||
| Q3 24 | 0.2% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 7.25× | 1.63× | ||
| Q3 25 | 2.49× | 1.59× | ||
| Q2 25 | 6.05× | 1.23× | ||
| Q1 25 | 22.92× | 1.11× | ||
| Q4 24 | 6.75× | 1.40× | ||
| Q3 24 | -0.96× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
